Treatment of dystrophinopathies with microdystrophin gene therapy constructs
Inventors
Qiao, Chunping • McDougald, Devin • Liu, Ye • Danos, Olivier
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Provided are gene constructs that encode a microdystrophin protein for use in gene therapy. The microdystrophin gene constructs and expression cassettes were engineered for improved therapy with respect to efficacy, potency and safety to the subject when expressed by a viral vector in muscle cells and/or CNS cells.
Core Innovation
The patent describes recombinant adeno-associated virus (rAAV) particles comprising nucleic acid encoding a microdystrophin, for delivery to muscle in treating dystrophinopathy in a human subject or for delivery to a cell. The microdystrophin comprises an H3 domain and a C-terminal domain with an α1-syntrophin binding site, or is defined by specified microdystrophin sequences. The compositions comprise cassette variants with distinct regulatory elements and microdystrophin domain configurations.
Expression cassettes comprise muscle-specific transcription regulatory elements, such as the SPc5-12 promoter, together with AAV2 inverted terminal repeats, polyadenylation sequences, and capsid proteins. CpG depletion in the expression constructs is intended to reduce immune recognition. The claims cover both treatment of human subjects by administering the rAAV particles and delivery of the microdystrophin-encoding nucleic acid to cells.
Experimental disclosures report evaluating AAV microdystrophin vectors in mdx mice, in which RGX-DYS1, RGX-DYS3, and RGX-DYS5 reduce elevated Pax7 expression, consistent with improved muscle-regeneration pathology. The disclosures also describe microdystrophin expression, restoration of dystrophin-associated proteins, and improved muscle strength and force, including grip strength for RGX-DYS1.
Claims Coverage
The patent includes eight independent claims directed to methods of treating dystrophinopathy in a human subject and methods of delivering microdystrophin-encoding nucleic acid to a cell, defining eight inventive features.
Treatment of dystrophinopathy using a microdystrophin related to SEQ ID NO: 79
Administering an rAAV particle encoding a microdystrophin at least 97% identical to SEQ ID NO: 79, comprising an H3 domain and a C-terminal domain with an α1-syntrophin binding site, resulting in delivery of microdystrophin to the muscle of a human subject.
Treatment of dystrophinopathy using a microdystrophin related to SEQ ID NO: 1
Administering an rAAV particle encoding a microdystrophin at least 97% identical to SEQ ID NO: 1, comprising an H3 domain and a C-terminal domain with an α1-syntrophin binding site, resulting in delivery of microdystrophin to the muscle of a human subject.
Cell delivery of nucleic acid encoding a microdystrophin related to SEQ ID NO: 79
Contacting a cell with an rAAV particle comprising nucleic acid encoding a microdystrophin at least 97% identical to SEQ ID NO: 79, comprising an H3 domain and a C-terminal domain with an α1-syntrophin binding site, delivering the nucleic acid to the cell.
Cell delivery of nucleic acid encoding a microdystrophin related to SEQ ID NO: 1
Contacting a cell with an rAAV particle comprising nucleic acid encoding a microdystrophin at least 97% identical to SEQ ID NO: 1, comprising an H3 domain and a C-terminal domain with an α1-syntrophin binding site, delivering the nucleic acid to the cell.
Treatment using specified microdystrophin and transcription regulatory element sequences
Administering an rAAV particle comprising nucleic acid encoding the microdystrophin of SEQ ID NO: 1 and a transcription regulatory element comprising the nucleotide sequence of SEQ ID NO: 39, resulting in delivery of microdystrophin to the muscle of a human subject.
Treatment using a specified AAV2 ITR and SPc5-12 cassette
Administering an rAAV particle comprising, in 5′-to-3′ order, a first AAV2 ITR, an SPc5-12 promoter, a sequence encoding the microdystrophin of SEQ ID NO: 1, a polyadenylation sequence, and a second AAV2 ITR, resulting in delivery of microdystrophin to the muscle of a human subject.
Cell delivery using an SPc5-12 promoter
Contacting a cell with an rAAV particle comprising nucleic acid encoding the microdystrophin of SEQ ID NO: 1 and an SPc5-12 promoter comprising the nucleotide sequence of SEQ ID NO: 39, delivering the nucleic acid and promoter to the cell.
Cell delivery using a specified AAV2 ITR and SPc5-12 cassette
Contacting a cell with an rAAV particle comprising first and second AAV2 ITRs, an SPc5-12 promoter, a sequence encoding the microdystrophin of SEQ ID NO: 1, a polyadenylation sequence, and a capsid protein, delivering the encoding nucleic acid to the cell.
The independent claims cover rAAV-mediated treatment of dystrophinopathy via delivery to muscle and rAAV-mediated delivery of microdystrophin-encoding nucleic acid to cells. Their claim elements specify microdystrophin sequence variants and domain architectures, transcription regulatory elements including the SPc5-12 promoter, and AAV2 vector cassette arrangements.
Stated Advantages
In mdx mice, RGX-DYS1, RGX-DYS3, and RGX-DYS5 reduce elevated Pax7 expression, consistent with improved muscle-regeneration pathology.
Improved muscle-function measures are reported in treated in vivo models such as mdx mice, including improved muscle force and grip strength for RGX-DYS1 and improved muscle strength.
Microdystrophin expression and restoration of dystrophin-associated proteins are reported.
Reduced markers of muscle regeneration and increased reporter expression with the VH4 intron are reported.
CpG depletion in the expression constructs is intended to reduce immune recognition.
Documented Applications
Treatment of dystrophinopathy in a human subject, including Duchenne muscular dystrophy, Becker muscular dystrophy, X-linked dilated cardiomyopathy, and female carriers of Duchenne or Becker muscular dystrophy.
Delivery of microdystrophin-encoding nucleic acid to a cell using an rAAV particle, including identified delivery to muscle, cardiac, and CNS tissues.
Evaluation of AAV microdystrophin vectors in mdx mice, and evaluating therapeutic efficacy.
Interested in licensing this patent?